CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Karimova, Madina ^a   Beschorner, Niklas ^a   Dammermann, Werner ^b   Chemnitz, Jan ^a   Indenbirken, Daniela ^a   Bockmann, Jan Hendrik ^b   Grundhoff, Adam ^a,c   Luth, Stefan ^b   Buchholz, Frank ^d   Wiesch, Julian Schulze Zur ^b,c   Hauber, Joachim ^a,c  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c German Center for Infection Research ^*  (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE I;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; GENE SILENCING; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; OPEN READING FRAME; VIRUS GENOME;

CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DEOXYRIBONUCLEASE I; GENE SILENCING; GENOME, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; OPEN READING FRAMES;

EID: 84940861401     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13734     Document Type: Article

References (66)

1. Liaw, Y. F., Chu, C. M. Hepatitis B virus infection. Lancet 373, 582-592 (2009).
2. Gerlich, W. H. Medical virology of hepatitis B: how it began and where we are now. Virol. J. 10, 239 (2013).
3. You, C. R., Lee, S. W., Jang, J. W., Yoon, S. K. Update on hepatitis B virus infection. World J. Gastroenterol. 20, 13293-13305 (2014).
4. Ganem, D., Prince, A. M. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 350, 1118-1129 (2004).
5. Block, T. M., Guo, H., & Guo, J. T. Molecular virology of hepatitis B virus for clinicians. Clin. Liver Dis. 11, 685-706, vii (2007).
6. Pujol, F. H., Navas, M. C., Hainaut, P., Chemin, I. Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett. 286, 80-88 (2009).
7. Sunbul, M. Hepatitis B virus genotypes: global distribution and clinical importance. World J. Gastroenterol. 20, 5427-5434 (2014).
8. Feitelson, M. A., Lee, J. Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett. 252, 157-170 (2007).
9. Dienstag, J. L. Hepatitis B virus infection. N. Engl. J. Med. 359, 1486-1500 (2008).
10. Bhattacharya, D., Thio, C. L. Review of hepatitis B therapeutics. Clin. Infect. Dis. 51, 1201-1208 (2010).
11. Zoulim, F. Are novel combination therapies needed for chronic hepatitis B? Antiviral Res. 96, 256-259 (2012).
12. Protzer, U., Maini, M. K., Knolle, P. A. Living in the liver: hepatic infections. Nat. Rev. Immunol. 12, 201-213 (2012).
13. Block, T. M. et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 98, 27-34 (2013).
14. Zoulim, F. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance? Antivir. Chem. Chemother. 15, 299-305 (2004).
15. Levrero, M. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581-592 (2009).
16. Lucifora, J. et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343, 1221-1228 (2014).
17. Liu, F. et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS. Pathog. 9, e1003613 (2013).
18. Li, G. Q., Gu, H. X., Li, D., Xu, W. Z. Inhibition of Hepatitis B virus cccDNA replication by siRNA. Biochem. Biophys. Res. Commun. 355, 404-408 (2007).
19. Gaj, T., Gersbach, C. A., Barbas, C. F., III ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397-405 (2013).
20. Zimmerman, K. A., Fischer, K. P., Joyce, M. A., Tyrrell, D. L., Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J. Virol. 82, 8013-8021 (2008).
21. Cradick, T. J., Keck, K., Bradshaw, S., Jamieson, A. C., McCaffrey, A. P. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol. Ther. 18, 947-954 (2010).
22. Weber, N. D. et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS. One. 9, e97579 (2014).
23. Bloom, K., Ely, A., Mussolino, C., Cathomen, T., Arbuthnot, P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol. Ther. 21, 1889-1897 (2013).
24. Chen, J. et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Molecular Therapy 22, 303-311 (2014).
25. Lin, S. R. et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol. Ther. Nucleic Acids 3, e186 (2014).
26. Seeger, C., Sohn, J. A. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol. Ther. Nucleic Acids 3, e216 (2014).
27. Kennedy, E. M. et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476C, 196-205 (2014).
28. Zhen, S. et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 22, 404-412 (2015).
29. Weber, N. D., Aubert, M., Dang, C. H., Stone, D., Jerome, K. R. DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. Virology 454-455, 353-361 (2014).
30. Frock, R. L. et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33, 179-186 (2015).
31. Wang, X. et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175-178 (2015).
32. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
33. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833-838 (2013).
34. Hsu, P. D., Lander, S., Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
35. Norder, H. et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47, 289-309 (2004).
36. Hayer, J. et al. HBVdb: a knowledge database for Hepatitis B Virus. Nucleic Acids Res. 41, D566-D570 (2013).
37. Kim, H. et al. Surrogate reporters for enrichment of cells with nuclease-induced mutations. Nat. Methods 8, 941-943 (2011).
38. Meyer, M., de Angelis, M. H., Wurst, W., Kuhn, R. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. Proc. Natl. Acad. Sci. USA 107, 15022-15026 (2010).
39. Sells, M. A., Chen, M. L., Acs, G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84, 1005-1009 (1987).
40. Protzer, U. et al. Antiviral activity and hepatoprotection by heme oxygenase-1in hepatitis B virus infection. Gastroenterology 133, 1156-1165 (2007).
41. Donnelly, M. L. et al. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Virol. 82, 1027-1041 (2001).
42. Iwamoto, M. et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. Biochem. Biophys. Res. Commun. 443, 808-813 (2014).
43. Hoh, A. et al. HBV-infected HepG2hNTCP cells serve as a novel immunological tool to analyze the antiviral efficacy of CD8+ T cells in vitro. J. Virol. 89, 7433-7438 (2015).
44. Wong, D. K. et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin. Gastroenterol. Hepatol. 11, 1004-1010 (2013).
45. Cheng, P. N. et al. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J. Med. Virol. 83, 602-607 (2011).
46. Bertoletti, A., Rivino, L. Hepatitis B: future curative strategies. Curr. Opin. Infect. Dis. 6, 528-534 (2014).
47. Chang, J., Guo, F., Zhao, X., Guo, J. T. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharmaceutica Sinica B 4, 248-257 (2014).
48. Kapoor, R., Kottilil, S. Strategies to eliminate HBV infection. Future. Virol. 9, 565-585 (2014).
49. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
50. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822-826 (2013).
51. Kuscu, C., Arslan, S., Singh, R., Thorpe, J., Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 32, 677-683 (2014).
52. Lin, Y. et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473-7485 (2014).
53. Shen, B. et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods 11, 399-402 (2014).
54. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132-141 (2014).
55. Bouchard, M. J., Schneider, R. J. The enigmatic X gene of hepatitis B virus. J. Virol. 78, 12725-12734 (2004).
56. Schiffer, J. T., Swan, D. A., Stone, D., Jerome, K. R. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS. Comput. Biol. 9, e1003131 (2013).
57. Buning, H., Perabo, L., Coutelle, O., Quadt-Humme, S., Hallek, M. Recent developments in adeno-associated virus vector technology. J. Gene Med. 10, 717-733 (2008).
58. Samulski, R. J., Muzyczka, N. AAV-mediated gene therapy for research and therapeutic purposes. Annual Review of Virology 1, 427-451 (2014).
59. Brunetti-Pierri, N., Ng, P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum. Mol. Genet. 20, R7-13 (2011).
60. Wang, Z. et al. Adenoviral delivery of recombinant hepatitis B virus expressing foreign antigenic epitopes for immunotherapy of persistent viral infection. J. Virol. 88, 3004-3015 (2014).
61. De Pietri, T. D. et al. Single-cell detection of microRNAs in developing vertebrate embryos after acute administration of a dualfluorescence reporter/sensor plasmid. Biotechniques 41, 727-732 (2006).
62. Hauber, I. et al. Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. PLoS. Pathog. 9, e1003587 (2013).
63. Dull, T. et al. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463-8471 (1998).
64. Beyer, W. R., Westphal, M., Ostertag, W., von Laer, D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J. Virol. 76, 1488-1495 (2002).
65. Laras, A., Koskinas, J., Dimou, E., Kostamena, A., Hadziyannis, S. J. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44, 694-702 (2006).
66. Chen, Y., Sze, J., He, M. L. HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage. World J. Gastroenterol. 10, 82-85 (2004).